...
首页> 外文期刊>Metabolic syndrome and related disorders >Metabolic and Cardiovascular Effects of Switching Thiazides to Amlodipine in Hypertensive Patients With and Without Type 2 Diabetes (the Diuretics and Diabetes Control Study)
【24h】

Metabolic and Cardiovascular Effects of Switching Thiazides to Amlodipine in Hypertensive Patients With and Without Type 2 Diabetes (the Diuretics and Diabetes Control Study)

机译:用2型糖尿病患者(利尿剂和糖尿病对照研究)的高血压患者切换噻嗪对氨氯地平的代谢和心血管作用(利尿剂和糖尿病对照研究)

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Different studies have indicated that thiazide diuretics can increase the risk of developing type 2 diabetes (T2D). Therefore, in this study, we investigated whether switching from hydrochlorothiazide (HCTZ) to amlodipine resulted in ameliorating different cardiovascular and metabolic measures in hypertensive patients with or without T2D. Methods: This study [Diuretics and Diabetes Control (DiaDiC)] was a 6-week, single-blind, single-center randomized controlled trial. The first 20 normal glucose-tolerant, 20 prediabetic, and 20 T2D consecutive patients were randomized to continue the previous antihypertensive treatment with HCTZ (12.5-25 mg/day) or to switch from HCTZ to amlodipine (2.5-10 mg/day). The primary endpoints were the absolute change in 7-day continuous subcutaneous glucose monitoring (CSGM) glycemia, serum uric acid concentrations, and endothelial function [measured as flow-mediated dilation (FMD)]. Other secondary endpoints were investigated, including changes in glycated hemoglobin (HbA(1)c), glycemic variability from 7-day CSGM, and the estimated glomerular filtration rate (eGFR). Results: Amlodipine treatment was associated with a significant reduction in HbA(1)c (P = 0.03) for both 7-day CSGM glycemia (P = 0.01) and glycemic variability (coefficient of variability %: HCTZ +3%, amlodipine -2.8%), and a reduction in uric acid concentrations (P < 0.001), especially in participants with T2D or prediabetes. Following amlodipine treatment, a significant increase in both eGFR (P = 0.01) and FMD (P = 0.02) was also observed. Conclusions: This study demonstrates that the replacement of HCTZ with amlodipine has several metabolic and cardiovascular beneficial effects. However, further intervention studies are necessary to confirm the clinical effects of thiazides, especially in diabetic people and in those at risk of diabetes.
机译:背景:不同的研究表明,噻嗪利剂可以增加发育2型糖尿病(T2D)的风险。因此,在本研究中,我们研究了从氢氯噻嗪(HCTZ)转换为氨氯噻e,导致改善有或没有T2D的高血压患者的不同心血管和代谢措施。方法:本研究[利尿剂和糖尿病对照(双糖尿病)是6周,单盲,单中心随机对照试验。第一种20正常葡萄糖,20个预脂肪剂和20T2D连续患者被随机化,以继续使用HCTZ(12.5-25mg /天)的先前抗高血压治疗,或从HCTZ切换到氨氯堇(2.5-10mg /天)。主要终点是7天连续皮下葡萄糖监测(CSGM)糖血症,血清尿酸浓度和内皮功能的绝对变化[测量为流动介导的扩张(FMD)]。研究了其他次要终点,包括糖化血红蛋白(HBA(1)c),血糖可变性的变化,从7天CSGM以及估计的肾小球过滤速率(EGFR)。结果:氨氯地平治疗与7天CSGM糖血症(P = 0.01)和血糖变异(可变性系数%:HCTZ + 3%,Amlodipine -2.8的HBA(1)C(p = 0.03)的显着降低有关。 %),以及降低尿酸浓度(P <0.001),尤其是在参与者的T2D或PrediaBetes中。在氨氯地平治疗后,还观察到EGFR(P = 0.01)和FMD(P = 0.02)的显着增加。结论:本研究表明,用氨氯地平替代HCTZ具有几种代谢和心血管的有益效果。然而,进一步的干预研究是确认噻嗪类化合物,特别是在糖尿病人物中的临床疗效,以及患有糖尿病风险的临床影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号